New liposomal irinotecan combo takes on pancreatic cancer in major trial

NCT ID NCT07238283

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial is testing whether a new combination of drugs (irinotecan liposome, oxaliplatin, 5-fluorouracil, and calcium folinate) works better than the current standard treatment (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who haven't had prior treatment. About 662 participants will be enrolled across multiple centers. The main goal is to see if the new combo helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Irinotecan hydrochloride liposome injection (II) combined with oxaliplatin, 5-fluorouracil, and calcium folinate
What this could lead to: If this works, it could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving survival compared to current standard therapy.
What could go wrong: This is a large Phase III trial, but the new combo may not prove better or safer than the existing regimen. Pancreatic cancer is very hard to treat, so even if successful, benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.